OncoScreen-R
OncoScreen-R: Rapid test for colorectal and pancreatic cancers.
OncoScreen-R
Rapid Test for Colorectal and Pancreatic Cancer Detection
Overview:
OncoScreen-R is a high-performance lateral flow rapid test developed by OncoFirm Diagnostics, designed for the early detection of colorectal and pancreatic cancers. Leveraging the specificity of Thomsen-Friedenreich (TF) and Gal-GalNAc antigens, OncoScreen-R delivers accurate, reliable results in under 15 minutes using a small sample of blood, serum, or plasma.
Key Features:
- Cancer-Specific Antigens: Targets TF and Gal-GalNAc antigens, which are overexpressed in gastrointestinal and pancreatic tumors.
- Non-Invasive & Rapid: Requires minimal sample volume with results available at the point-of-care within minutes.
- High Sensitivity & Specificity: Engineered with enhanced nanoparticle signal amplification for accurate results.
- Ideal for Medical Institutions: Designed for hospitals, clinics, diagnostic labs, and oncology screening programs.
- Digital Integration-Ready: Compatible with smartphone apps and digital readers for real-time data collection and analysis.
Clinical Applications:
- Early screening for colorectal cancer (CRC) and pancreatic adenocarcinoma
- Risk assessment in patients with family history or pre-malignant GI symptoms
- Adjunct to imaging and endoscopy in underserved or resource-limited settings
- Monitoring of at-risk populations in oncology and gastroenterology clinics
Benefits to Healthcare Providers:
- Enhances early diagnosis in high-risk patients
- Reduces diagnostic delays in clinical settings
- Supports personalized treatment planning and follow-up strategies
Next Steps:
OncoScreen-R is currently available for CE-marked markets and undergoing further clinical validation. U.S. FDA regulatory pathways are in progress.
